Albireo gets FDA, European approval for pediatric liver disease drug
Albireo Pharma, a rare liver disease-focused biopharma spun out of AstraZeneca in 2008, has its first regulatory approval for a drug for a pediatric liver disease called progressive familial intrahepatic cholestasis (PFIC).
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Rowan Walrath Source Type: news
More News: AstraZeneca | Biotechnology | Cholestasis | Health Management | Liver | Liver Disease | Obstetric Cholestasis | Pediatrics | Pharmaceuticals | Urology & Nephrology